About the Company
Cortexyme, Inc. is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer's and other degenerative diseases. Based upon the evidence generated to date, Cortexyme is currently advancing its lead therapeutic candidate, atuzaginstat (COR388), in the GAIN Trial, an ongoing Phase 2/3 clinical trial in patients with mild to moderate Alzheimer's disease. Cortexyme is targeting a specific, infectious pathogen found in the brain and other organs and tied to degeneration and inflammation in humans and animal models.
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
Employees
38
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $CRTX News
Quince Therapeutics Inc (QNCX)
LifeSci Capital analyst David Sherman maintained a Buy rating on Cortexyme (NASDAQ:CRTX) Inc on Tuesday, setting a price target of $221, which is approximately 123.44% above the ...
Researchers Link Gum Disease to Alzheimer’s
In a paper published in Science Advances, private pharmaceutical company Cortexyme details the role of Porphyromonas gingivalis – a common bacterium linked to chronic gum disease – in driving ...
PFIZER INC's Net Worth
PFIZER INC has an estimated net worth of $2.44 Billion. This is based on reported shares across multiple companies, which include BioAtla, Inc., Viatris Inc, Cerevel Therapeutics Holdings, Inc ...
Welcome to Inc.'s Directory of B2B Excellence
They all made it through Inc.'s proprietary vetting process, based in part on testimonials from other clients. As any entrepreneur knows, the right partnership can make all the difference.
TAKEDA PHARMACEUTICAL CO LTD's Net Worth
Who is TAKEDA PHARMACEUTICAL CO LTD? TAKEDA PHARMACEUTICAL CO LTD has an estimated net worth of $461 Million. This is based on reported shares across multiple companies, which include Calithera ...
About Inc.com | Everything You Need to Know to Grow and Start Your Business
Inc. is the voice of the American entrepreneur. We inspire, inform, and document the most fascinating people in business: the risk-takers, the innovators, and the ultra-driven go-getters that ...
Snap Inc.
No significant news for in the past two years. Key Stock Data P/E Ratio (TTM) The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...
Apple Inc.
No significant news for in the past two years. Key Stock Data P/E Ratio (TTM) The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...
Tesla, Inc. (TSLA)
Tesla will report Q1 earnings after the bell on Tuesday, giving a much-needed update on the EV maker’s current and future prospects as investor sentiment slides. Tesla (TSLA) is asking ...
‘Food, Inc. 2’ Review: A Second Course
Share full article “Food, Inc. 2,” directed by Robert Kenner and Melissa Robledo, begins by describing how the last few years have shown the risks of letting a handful of mega-suppliers ...
Macy's, Inc. (M)
Vanguard Small Cap Value Index Fund 4.81M Dec 31, 2023 1.75% 89,121,520 Vanguard Extended Market Index Fund 4.05M Dec 31, 2023 1.47% 75,050,783 Avantis U.S. Small Cap Value Fund 3.32M Dec 31, 2023 ...
Quince Therapeutics Inc (QNCX)
For Immediate ReleaseChicago, IL –December 12, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts ...
Loading the latest forecasts...